Ligand Pharma (LGND) Tops Q3 EPS by 29c, Revenues Beat; Raises FY18 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Ligand Pharma (LGND) Tops Q3 EPS by 29c, Revenues Beat; Raises FY18 Revenue Guidance Above Consensus

Ligand Reports Third Quarter 2018 Financial Results

November 8, 2018 8:00 AM EST

Raises 2018 Financial Guidance

Conference Call Begins at 9:00 a.m. Eastern Time Today

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2018, and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 9:00 a.m. Eastern time to discuss this announcement and answer questions.

This quarter was marked by several events that demonstrate the strength of Ligands business model. First, our partners continued to deliver... More